Amyris, Inc., a vertically integrated biomanufacturing company based in Emeryville, Calif., announced that it will acquire Oobli Inc., a Davis, Calif.-based developer of fermentation-derived sweet proteins. The acquisition is expected to close in the coming weeks. Amyris said existing customer commitments and brand partnerships would continue to be honored without interruption.
Amyris said the transaction brings its scientific capabilities and manufacturing depth together with Oobli’s protein fermentation expertise. The move follows Amyris’ expansion earlier this year of manufacturing capacity at its advanced fermentation facility in Barra Bonita, Brazil. Amyris described the acquisition as a strategic commercial and technology expansion intended to accelerate its presence in protein- and peptide-based solutions across end markets.
Sweet protein platform
Oobli’s commercial portfolio of sweet proteins would be the first to benefit from the combined platform. Oobli said it has spent the past decade refining a fermentation process to produce sweet proteins that are naturally found in rare fruits and berries near the equator. According to the company, these proteins are hundreds to thousands of times sweeter than sugar, bind directly to sweet taste receptors and are metabolized by the body as protein, providing sweetness without gut disruption or blood sugar spikes.
The portfolio includes Oubli Fruit, Serendipity Berry and Katemfe Fruit Sweet Proteins, known scientifically as brazzein, monellin and thaumatin, respectively. The portfolio has FDA GRAS status as an ingredient and is FEMA GRAS-affirmed for use as a natural flavor. The ingredients are positioned for use across sports nutrition, dairy, beverages, chocolate, bakery and confectionery, where brands are seeking ways to reduce sugar as consumer awareness of metabolic health grows.
Executive views
Amyris CEO Kathy Fortmann said Oobli offers a commercial and technology platform that complements Amyris. She said Amyris aims to bring its commercial scale and resources to accelerate what the company calls the sweet revolution. By combining Oobli’s protein expertise with Amyris’ strain engineering, manufacturing scale and commercial capabilities, Fortmann said, the companies see potential to broaden capabilities in food and beverage, personal care, flavor and fragrance, agriculture and beyond.
Oobli CEO Ali Wing said the company has long believed there is a better way to deliver the sweet taste consumers want without trade-offs to health and the environment. She said joining Amyris would give Oobli the scale and resources to pursue its ambition of making sweet proteins a global standard in sweetness solutions.
Fortmann added that Amyris has seen biomanufactured solutions succeed when they align with consumer demand and market needs. She said Oobli’s platform does that by giving brands a way to address sweet taste, sugar reduction and clean label at the same time. Amyris said it looks forward to welcoming the Oobli team and realizing synergies between the two platforms.
